Mein Warenkorb

Monoclonal Anti-Influenza A [Victoria/4897/2022] HA (H1N1) Antibody, Human IgG1 (3F3)

User Reviews
Product Number/Spec
Price
Availability
Menge
HA1-MY2156-100ug
$350.00
In Stock - Delivery in 2-3 business days
HA1-MY2156-1mg (500ug X 2)
$2310.00
In Stock - Delivery in 2 weeks
Gesamtanzahl Product Amount$ 0

Product Details

  • Source

    Chimeric Monoclonal Anti-Influenza A [Victoria/4897/2022] HA (H1N1) Antibody, Human IgG1 (3F3) is recombinantly expressed in HEK293. It consists of mouse variable regions genetically fused to human IgG1 constant domains.

  • Antibody Type

    Recombinant Monoclonal

  • Clone

    3F3

  • Isotype

    Human IgG1, Kappa

  • Host Species

    Mouse

  • Reactivity

    Virus

  • Immunogen

    Recombinant Influenza A [Victoria/4897/2022] Hemagglutinin (HA) Protein is expressed from human 293 cells

  • Specificity

    Specifically recognizes Influenza A [Victoria/4897/2022] Hemagglutinin (HA).

  • Application

    Application
    Recommended Use / Performance
    ELISA
    0.2-2 μg/mL
  • Cross Verification

    This product No cross-reactivity in ELISA with
    Influenza A [A/Hong Kong/483/97 (H5N1)] HA, His Tag (Cat. No. HA1-V5229).
    Influenza A [A/Victoria/2570/2019] Hemagglutinin (HA) Protein, His Tag (Cat. No. HA1-V52H6).
    Influenza A [A/Darwin/6/2021 (H3N2)] HA Protein, His Tag (Cat. No. HA2-V52H5).
    Influenza A [A/Darwin/9/2021 (H3N2)] HA Protein, His Tag (Cat. No. HA2-V52H6).
    Influenza A (Vietnam/1194/2004(H5N1)) Hemagglutinin (HA) Protein, His Tag (Cat. No. HA1-V52H9).
    Influenza A (Guangdong/18SF020(H5N6)) Hemagglutinin (HA) Protein, His Tag (Cat. No.HA6-V52H3).
    Influenza A (turkey/Germany-MV/R2472/2014(H5N8)) HA Protein, His Tag (Cat. No. HA8-V52H3).
    Influenza A (A/Shanghai/02/2013(H7N9)) Hemagglutinin (HA) Protein, His Tag (Cat. No. HA9-V52H3).
    Influenza A [A/guinea fowl/Hong Kong/WF10/99(H9N2)] Hemagglutinin (HA) Protein, His Tag (Cat. No. HA2-V52H7).
    Influenza B [Austria/1359417/2021 (B/Victoria lineage)] Hemagglutinin (HA) Protein, His Tag (Cat. No. HAE-V52H3).
    Influenza B [Phuket/3073/2013 (B/Yamagata lineage)] HA Protein, His Tag (Cat. No. HAE-V52H4).
    Influenza A [A/Bangkok/1/1979 (H3N2)] HA, His Tag (Cat. No. HA2-V52H3).
    Influenza A [A/Wisconsin/588/2019 (H1N1)] HA, His Tag (Cat. No. HA1-V52H3).

  • Purification

    Protein A purified.

  • Aggregation

    Less than 10%, as determined by SEC-MALS.

  • Concentration

    Please refer to the Certificate of Analysis (CoA).

  • Form

    Lyophilized

  • Formulation

    Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Reconstitution

    Please refer to the Certificate of Analysis (CoA) for specific instructions.

  • Shipping

    Lyophilized product is shipped at ambient temperature.

  • Storage

    For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Kunden haben auch angesehen

Data Display

  • Bioactivity-ELISA

     Hemagglutinin/HA (Influenza Virus) ELISA

    Immobilized Influenza A [Victoria/4897/2022] Hemagglutinin (HA) Protein, His Tag (Cat. No. HA1-V52H8) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Influenza A [Victoria/4897/2022] HA (H1N1) Antibody, Human IgG1 (3F3) (Cat. No. HA1-MY2156) with a linear range of 0.06-1 ng/mL (QC tested).

    Protocol
  •  Hemagglutinin/HA (Influenza Virus) ELISA

    Immobilized Influenza A [Wisconsin/67/2022] Hemagglutinin (HA) Protein, His Tag (Cat. No. HA1-V52H7), Influenza A [Sydney/5/2021 (H1N1)] HA Protein, His Tag (Cat. No. HA1-V52H4) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Influenza A [Victoria/4897/2022] HA (H1N1) Antibody, Human IgG1 (3F3) (Cat. No. HA1-MY2156) with a linear range of 0.01-2 ng/mL (Routinely tested).

    Protocol

User Reviews
Publish Comment

FAQ

  • product

    Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?

    In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.


    Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.


    To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.


    To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.


    Supporting Document


Background Introduction

Influenza, commonly known as 'the flu', is an infectious disease of birds and mammals caused by RNA viruses of the family Orthomyxoviridae, the influenza viruses. The virus is divided into three main types (Influenzavirus A, Influenzavirus B, and Influenzavirus C), which are distinguished by differences in two major internal proteins (hemagglutinin (HA) and neuraminidase (NA), which are the most important targets for the immune system. Hemagglutinin binds to the sialic acid-containing receptors on the surface of host cells during initial infection and at the end of an infectious cycle which makes it a great target for vaccine studies.

Frontier Progress

 
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Kunden haben auch angesehen
  • Data Display
  • User Reviews
  • FAQ
  • Hintergrund
Kontaktieren Sie uns